Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients
(2019) In Radiotherapy and Oncology 130. p.149-155- Abstract
Background: We sought to assess the influence of the clinical introduction of new radiotherapy technologies on glioblastoma patients’ outcomes. Methods: Newly diagnosed glioblastoma patients treated with 60 Gy and temozolomide (2005–2014) were analyzed. The patients’ GTV and CTV were defined based on MR (n = 521) or FET-PET/MR (n = 190), and were treated using conformal radiotherapy (CRT, n = 159) or image-guided volumetric modulated arc therapy with hippocampal sparing (IG-VMAT, n = 362). Progression-free survival (PFS) was assessed using the McDonald criteria. Associations between clinical data, dosimetry data, treatment technology, for PFS and overall survival (OS) were explored. Results: The PFS (7 months) and OS (15 months) were... (More)
Background: We sought to assess the influence of the clinical introduction of new radiotherapy technologies on glioblastoma patients’ outcomes. Methods: Newly diagnosed glioblastoma patients treated with 60 Gy and temozolomide (2005–2014) were analyzed. The patients’ GTV and CTV were defined based on MR (n = 521) or FET-PET/MR (n = 190), and were treated using conformal radiotherapy (CRT, n = 159) or image-guided volumetric modulated arc therapy with hippocampal sparing (IG-VMAT, n = 362). Progression-free survival (PFS) was assessed using the McDonald criteria. Associations between clinical data, dosimetry data, treatment technology, for PFS and overall survival (OS) were explored. Results: The PFS (7 months) and OS (15 months) were unaffected by CRT, IG-VMAT and FET-PET technology. Mean brain dose was correlated with tumor volume, and was lower for IG-VMAT vs. CRT (p < 0.001). Larger mean brain dose was associated with inferior PFS (univariate/multivariate Cox models, p < 0.001) and OS (univariate, p < 0.001). Multivariate Cox models revealed association of larger mean brainstem dose (p < 0.001), BTV (p = 0.045), steroid use at baseline (p = 0.003), age (p = 0.019) and MGMT status (p = 0.022) with lower OS. Conclusions: Introduction of hippocampal-sparing IG-VMAT technology appeared to be safe, and may have reduced toxicity and cognitive impairment. Larger mean brain dose was strongly associated with inferior PFS and OS.
(Less)
- author
- Munck af Rosenschold, P. LU ; Law, I. ; Engelholm, S. ; Engelholm, S. A. ; Muhic, A. ; Lundemann, M. J. ; Roed, H. ; Grunnet, K. and Skovgaard Poulsen, H.
- publishing date
- 2019-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- FET-PET, Glioblastoma, IGRT, Radiotherapy, Technology, VMAT
- in
- Radiotherapy and Oncology
- volume
- 130
- pages
- 7 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:30446316
- scopus:85056392126
- ISSN
- 0167-8140
- DOI
- 10.1016/j.radonc.2018.10.003
- language
- English
- LU publication?
- no
- id
- 39840209-8084-4e2b-8df2-165c42e2a47a
- date added to LUP
- 2020-07-28 08:38:00
- date last changed
- 2024-09-19 04:35:57
@article{39840209-8084-4e2b-8df2-165c42e2a47a, abstract = {{<p>Background: We sought to assess the influence of the clinical introduction of new radiotherapy technologies on glioblastoma patients’ outcomes. Methods: Newly diagnosed glioblastoma patients treated with 60 Gy and temozolomide (2005–2014) were analyzed. The patients’ GTV and CTV were defined based on MR (n = 521) or FET-PET/MR (n = 190), and were treated using conformal radiotherapy (CRT, n = 159) or image-guided volumetric modulated arc therapy with hippocampal sparing (IG-VMAT, n = 362). Progression-free survival (PFS) was assessed using the McDonald criteria. Associations between clinical data, dosimetry data, treatment technology, for PFS and overall survival (OS) were explored. Results: The PFS (7 months) and OS (15 months) were unaffected by CRT, IG-VMAT and FET-PET technology. Mean brain dose was correlated with tumor volume, and was lower for IG-VMAT vs. CRT (p < 0.001). Larger mean brain dose was associated with inferior PFS (univariate/multivariate Cox models, p < 0.001) and OS (univariate, p < 0.001). Multivariate Cox models revealed association of larger mean brainstem dose (p < 0.001), BTV (p = 0.045), steroid use at baseline (p = 0.003), age (p = 0.019) and MGMT status (p = 0.022) with lower OS. Conclusions: Introduction of hippocampal-sparing IG-VMAT technology appeared to be safe, and may have reduced toxicity and cognitive impairment. Larger mean brain dose was strongly associated with inferior PFS and OS.</p>}}, author = {{Munck af Rosenschold, P. and Law, I. and Engelholm, S. and Engelholm, S. A. and Muhic, A. and Lundemann, M. J. and Roed, H. and Grunnet, K. and Skovgaard Poulsen, H.}}, issn = {{0167-8140}}, keywords = {{FET-PET; Glioblastoma; IGRT; Radiotherapy; Technology; VMAT}}, language = {{eng}}, month = {{01}}, pages = {{149--155}}, publisher = {{Elsevier}}, series = {{Radiotherapy and Oncology}}, title = {{Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients}}, url = {{http://dx.doi.org/10.1016/j.radonc.2018.10.003}}, doi = {{10.1016/j.radonc.2018.10.003}}, volume = {{130}}, year = {{2019}}, }